Helus Pharma CMO to Speak at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma's Chief Medical Officer will present at a key industry conference, highlighting the company's progress in developing novel treatments for depression and anxiety.
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists, announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The event, scheduled for June 15-16, 2026, will feature the fireside chat available on demand starting June 15 at 7:00 a.m. EDT. This participation underscores Helus Pharma's commitment to advancing its pipeline of proprietary serotonergic agonists (NSAs) designed to address major depressive disorder and generalized anxiety disorder.
The company's lead candidate, HLP003, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma's approach focuses on synthetic molecules that activate serotonin pathways believed to promote neuroplasticity, offering potential durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The H.C. Wainwright Neuro Perspectives Conference is a key industry event that brings together researchers, clinicians, and investors to discuss the latest developments in neuroscience. Inamdar's fireside chat will provide insights into Helus Pharma's clinical programs and the broader implications of its NSA platform. For more details on the announcement, the full press release is available at https://ibn.fm/KsnJW.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is dedicated to helping minds heal through innovative treatments. The company's proprietary NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape. For company updates, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Investors can access the latest news and updates at https://ibn.fm/HELP.
The participation of Helus Pharma's CMO at this conference signals the company's active engagement with the investment and scientific communities, providing a platform to discuss its progress in developing next-generation treatments for mental health disorders. As the company advances its clinical programs, the fireside chat will be an opportunity for stakeholders to gain a deeper understanding of the potential impact of its NSA platform on the treatment landscape.